Takeda Tracks Real-World Safety of Alunbrig in Japanese Lung Cancer Patients
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Takeda’s new post‑marketing survey, titled “General Use-results Survey of Alunbrig Tablets Non-small Cell Lung Cancer,” tracks how Alunbrig (brigatinib) is used in everyday care for lung cancer patients in Japan. The main goal is to monitor real‑world safety, with a focus on lung-related side effects that may not appear as clearly in controlled trials.
The study looks at brigatinib tablets, sold as Alunbrig, a targeted drug for a type of non-small cell lung cancer. Doctors prescribe the medicine as usual, while Takeda collects safety data to understand side effects and support long-term use in clinical practice.
This is an observational, prospective cohort study, meaning patients are followed over time without changing how they are treated. There is no random assignment or placebo, and no blinding, so the main purpose is safety tracking rather than showing how well the drug works compared with other options.
The project was first submitted on October 28, 2021, marking the formal start of the data collection effort. The latest update on March 15, 2026 signals that enrollment and follow‑up remain active, which keeps the study current and relevant for investors watching Alunbrig’s safety story.
Regular real‑world safety updates can support confidence in Takeda’s oncology portfolio and help sustain revenue from Alunbrig, even if near‑term sales impact is limited. Investors will also weigh these findings against competing ALK inhibitors from Roche, Novartis, and Pfizer, as clean safety data could strengthen Takeda’s positioning in a crowded lung cancer market.
The study is ongoing and has been recently updated, with full and current details available on the ClinicalTrials portal for further review.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
